Table II.
Clinical results of CK only or CK/CIK therapy.
| Characteristic | CK | CK/CIK cell therapy | P-value |
|---|---|---|---|
| Efficacy assessment (WHO; %) | 72.73 | 81.82 | 0.118 |
| KPS, mean ± SD | |||
| Before | 65.00±10.00 | 67.73±9.05 | 0.029 |
| After | 73.64±11.20 | 86.36±11.64 | |
| Tumor marker (CEA), mean ± SD | |||
| Before | 185.05±338.41 | 181.00±305.56 | 0.045 |
| After | 102.27±194.39 | 45.10±73.27 | |
| Phenotype of CIK cells before transfusion, mean ± SD (%) | |||
| CD3+/CD8+ (d12) | - | 57.08±16.94 | - |
| CD3+/CD56+ (d12) | - | 14.80±7.00 | - |
CK, CyberKnife; CIK, cytokine-induced killer; KPS, Karnofsky performance status; CEA, carcinoembryonic antigen.